Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Sunday, 20 May 2018

Gov UK: Press release: Crime doesn’t pay for imprisoned former bankrupt faced with losing ‘proceeds of crime home’

Press release: Crime doesn't pay for imprisoned former bankrupt faced with losing 'proceeds of crime home'
Read more

Press release: New laws to make social media safer
Read more

Press release: Foreign Secretary arrives in Peru for first visit of a British Foreign Secretary in over 50 years
Read more

Press release: Foreign Secretary arrives in Argentina ahead of G20 Foreign Ministers' meeting and lays a wreath to honour the Fallen of the Falkland Islands conflict
Read more

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Galapagos NV    

Published: 20:30 CEST 20-05-2018 /GlobeNewswire /Source: Galapagos NV / : GLPG /ISIN: BE0003818359

GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

 

Mechelen, Belgium; 20 May 2018; 20.30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces publication milestones on GLPG1690 in idiopathic pulmonary fibrosis (IPF). In addition to presenting three abstracts on investigational drug GLPG1690 at the American Thoracic Society Meeting (ATS) from 18 to 23 May in San Diego, California, USA, Galapagos announces the publication of the FLORA Phase 2a study results in the most recent issue of The Lancet Respiratory Medicine.

 

"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis: a phase 2a randomised placebo-controlled trial (FLORA trial)," by Prof. Dr. Toby Maher et al. describes the FLORA trial results and was published today in The Lancet Respiratory Medicine.

FLORA was an exploratory, randomized, double-blind, placebo-controlled trial investigating a once-daily oral dose of GLPG1690. The drug candidate was administered for 12 weeks in 23 IPF patients, 17 of whom received GLPG1690 and 6 of whom received placebo. Over the 12-week period, patients receiving GLPG1690 showed an FVC increase of 8 mL, while patients on placebo showed an FVC reduction of 87 mL (mean from baseline). GLPG1690 was well-tolerated by IPF patients in the FLORA trial.

 

"Although not without limitations, proof of concept studies are vital in addressing the huge unmet need for effective and well tolerated therapies for idiopathic pulmonary fibrosis, a progressive and inevitably fatal lung disease. Studies such as FLORA quickly support proof-of-concept of new treatment options, without unnecessarily exposing high-risk patients to investigational therapies of unknown efficacy for prolonged periods of time," said Dr. Toby Maher, British Lung Foundation Chair in Respiratory Research and Professor of Interstitial Lung Disease, Imperial College, London, in The Lancet Respiratory Medicine publication. "Although measuring effect of treatment was only a secondary, non-powered endpoint, the data from FLORA, particularly for FVC, are extremely encouraging and warrant further larger scale trials." A link to this publication can be found at www.glpg.com/glpg-1690.

 

At ATS in San Diego, the Galapagos team are in de midst of presenting the following abstracts:

 

Sunday May 20, 2018 9:15 AM - 4:15 PM - poster session

9869 - Pharmacodynamics and Pharmacokinetics of the Autotaxin Inhibitor GLPG1690 in the FLORA Trial: a Randomized, Placebo-controlled, Double Blind Phase IIa Clinical Trial of 12 Weeks in Individuals with Idiopathic Pulmonary Fibrosis

 

Sunday May 20, 2018 2:15 PM-4:15 PM - oral presentation

9097 - Randomized, Placebo-Controlled, Double Blind Phase IIa Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 12 Weeks of Treatment of an Autotaxin Inhibitor (GLPG1690) in Individuals with Idiopathic Pulmonary Fibrosis (FLORA Trial)

 

Tuesday May 22, 2018 2:15 PM - 4:15 PM - oral presentation

8893 - Assessment of the Effects of GLPG1690 in Idiopathic Pulmonary Disease (IPF) Patients Using Functional Respiratory Imaging (FRI)

 

More information can be found on http://conference.thoracic.org. All posters and presentations can be downloaded starting on 23 May from www.glpg.com/glpg-1690.

 


About GLPG1690

GLPG1690 is a small molecule, selective autotaxin inhibitor which is fully proprietary to Galapagos. Galapagos identified the autotaxin target using its proprietary target discovery platform and developed molecule GLPG1690 as an inhibitor of this target. Oral investigational drug GLPG1690 showed promising results in relevant pre-clinical models for IPF, and there is growing evidence in scientific literature that autotaxin plays a role in this disease. GLPG1690 appeared to halt disease progression as measured by FVC at 12 weeks and was well-tolerated by IPF patients in the FLORA Phase 2a trial reported in August 2017. Galapagos received orphan drug designation for GLPG1690 in IPF from the U.S. Food & Drug Administration (FDA) and European Commission (EC). In April 2018, Galapagos announced the design of a worldwide Phase 3 program, based on feedback from the FDA and the European Medicines Agency (EMA), to evaluate GLPG1690 in IPF patients. The planned ISABELA Phase 3 program with GLPG1690 is intended to support both New Drug Application (NDA) and Market Authorization Application (MAA) submissions in respectively the United States and European Union. GLPG1690 is an investigational drug and its efficacy and safety have not been established.

 

Preliminary information for patients and healthcare professionals can be found at www.isabelastudies.com. For more information about GLPG1690: www.glpg.com/glpg-1690.

 

About IPF

IPF is a chronic, relentlessly progressive fibrotic disorder of the lungs that typically affects adults over the age of 40. IPF affects approximately 200,000 patients in the United States and Europe and, as such, we have received orphan designation for our product candidate GLPG1690 in IPF from the European Commission and from the FDA. The clinical prognosis of patients with IPF is poor, as survival at diagnosis is two to four years. Currently, no medical therapies have been found to cure IPF. The medical treatment strategy aims to slow disease progression and improve quality of life. Lung transplantation may be an option for appropriate patients with progressive disease and minimal comorbidities.

 

Regulatory agencies have approved Esbriet®[1] (pirfenidone) and Ofev®[2] (nintedanib) for the treatment of mild to moderate IPF. Both Esbriet and Ofev have been shown to slow the rate of functional decline in IPF and are gaining ground as the standard of care worldwide. Combined sales of both drugs reached $1.1 billion in 2016, with 74% of global revenues being in the United States. These regulatory approvals represent a major breakthrough for IPF patients; yet the disease in most patients on these therapies continues to progress. Therefore, there is still a large unmet medical need as IPF remains a major cause of morbidity and mortality. We estimate global sales of approved IPF drugs will grow to nearly $5 billion in 2025.

 

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos' pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic pulmonary fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 634 employees, operating from its Mechelen, Belgium headquarters and facilities in the Netherlands, France, Switzerland, the United States and Croatia. More information available at www.glpg.com.

 

Contacts

 

Investors:

Elizabeth Goodwin

VP IR & Corporate Communications

+1 781 460 1784

 

Paul van der Horst

Director IR & Business Development

+31 71 750 6707

ir@glpg.com

 

Media:

Evelyn Fox

Director Communications

+31 6 53 591 999

communications@glpg.com

 

 

Forward-looking statements

This release may contain forward-looking statements, including, among other things, statements regarding Galapagos' strategic ambitions, the mechanism of action and potential activity of GLPG1690, the anticipated timing of future clinical trials with GLPG1690, the progression and results of such trials, and Galapagos' interactions with regulatory authorities. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that Galapagos' expectations regarding its GLPG1690 development program may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from Galapagos' ongoing clinical research programs may not support registration or further development of GLPG1690 due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties, and estimating the commercial potential of GLPG1690. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on Form 20-F filed with the SEC and other filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

 



[1] Esbriet® (pirfenidone) is indicated for the treatment of IPF by Roche/Genentech.

[2] Ofev® (nintedanib) is indicated for the treatment of IPF by Boehringer Ingelheim.

 

 




GLPG1690 Publications



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Galapagos NV, Industriepark Mechelen Noord I, zone L
Generaal De Wittelaan L11 A3, Mechelen B-2800 , Belgie
If you would like to unsubscribe and stop receiving these e-mails click here.

NanoScientific, the Journal for Nanotechnology Launches New Web Version Showcasing Pioneering Research and Applications

 
NanoScientific, the Journal for Nanotechnology Launches New Web Version Showcasing Pioneering Research and Applications
SANTA CLARA, Calif., May 19, 2018 /PRNewswire/ -- NanoScientific, a popular nanoscience magazine is pleased to announce the launch of their web version, www.nanoscientific.org, an online portal featuring pioneering future oriented news and articles on Nanotechnology research and appli...
Read more

Midea Unveils Cutting-edge RF FlashThawer At 2018 National Restaurant Association Showcase
CHICAGO, May 19, 2018 /PRNewswire/ -- Leading appliance supplier Midea has unveiled its revolutionary FlashThawer for the professional Food & Beverage (F&B) industry at the 2018 National Restaurant Association Showcase (NRA Show), which harnesses radio frequency (RF)...
Read more

YIBAIFEN Standing Out as Leaders of Social E-commerce in China
Rewards Top Company Agents SHENZHEN, China, May 20, 2018 /PRNewswire/ -- Social E-commerce A New Business Model Social e-commerce is a derivative e-commerce mode. It is based on interpersonal relationship networks, with the help of a social media propagation path like...
Read more

A Royal Pajama Party in Vegas! The Wedding Capital of the World Went All-In for Harry & Meghan's Big Day as Only Vegas Could
Link to B-roll footage below LAS VEGAS, May 20, 2018 /PRNewswire/ -- The city continued to celebrate what was named Royal Wedding Month by throwing a blow-out pajama party at Topgolf Las Vegas complete with royal guards, tea and shortbread, delectable finger sandwiches, props for a...
Read more

Pegasus Food Futures Announces Appointment of Stefanie Paterson as Head of Human Resources
ABU DHABI, United Arab Emirates, May 20, 2018 /PRNewswire/ -- Pegasus Food Futures, one of the largest owners and operators of hydroponic farming facilities in the Middle East and North Africa (MENA) today announced the appointment of Stefanie Paterson as Head of Human Resources, who...
Read more

Mundipharma and Endoceutics to Exclusively License Intrarosa™ (Prasterone) in MEA Region
DUBAI, UAE, May 20, 2018 /PRNewswire/ -- A unique non-estrogen prescription therapy, Intrarosa™, has been approved by the US Food and Drug Administration (FDA) and by the European Medical Agency (EMA), for the treatment of the most bothersome symptom of vulvovaginal atrophy, due to...
Read more

Dubai Moves to Honour Knowledge Pioneer With $1 Million Mohammed bin Rashid Al Maktoum Knowledge Award
DUBAI, UAE, May 20, 2018 /PRNewswire/ -- The submission deadline for this fifth edition has been set for June 25, 2018  The Mohammed bin Rashid Al Maktoum Knowledge Award has announced it is now open for submissions. The fifth edition of the annual programme wi...
Read more

Europa in beweging: Commissie voltooit haar agenda voor veilige, schone en geconnecteerde mobiliteit

Stuur deze nieuwsbrief door naar andere ondernemers!
Beste ,
Alstublieft, het actuele ondernemersnieuws.
De redactie.

Europa in beweging: Commissie voltooit haar agenda voor veilige, schone en geconnecteerde mobiliteit

Lees meer
share on Twitter Like Europa in beweging: Commissie voltooit haar agenda voor veilige, schone en geconnecteerde mobiliteit on Facebook

OKI voegt landenteams samen in één centrale regio

Lees meer
share on Twitter Like OKI voegt landenteams samen in één centrale regio on Facebook

Why Amazon and Jeff Bezos Are So Successful at Disruption

Lees meer
share on Twitter Like Why Amazon and Jeff Bezos Are So Successful at Disruption on Facebook

Zo wijzig je de stem van Google Assistant

Lees meer
share on Twitter Like Zo wijzig je de stem van Google Assistant on Facebook

Nieuwe evenementen waar je bij wilt zijn zoals: TNW Conference 2018

Lees meer
share on Twitter Like Nieuwe evenementen waar je bij wilt zijn zoals: TNW Conference 2018 on Facebook

'Mkb krijgt prominente rol in nieuwe exportstrategie kabinet'

Lees meer
share on Twitter Like 'Mkb krijgt prominente rol in nieuwe exportstrategie kabinet' on Facebook

Vrachtwagen weiland ingereden langs A73 [+foto]

Lees meer
share on Twitter Like Vrachtwagen weiland ingereden langs A73 [+foto] on Facebook

30-05-2018: Expertsessie over Voorbereiding Financiering (door: KvK i.s.m. Credion)

Lees meer
share on Twitter Like 30-05-2018: Expertsessie over Voorbereiding Financiering (door: KvK i.s.m. Credion) on Facebook

Twee oudste kolencentrales van Nederland moeten in 2024 dicht zijn

Lees meer
share on Twitter Like Twee oudste kolencentrales van Nederland moeten in 2024 dicht zijn on Facebook

Aanbesteding: Best Value aanbesteding Rehabilitatie Kunstwerken (P16009) - Provincie Overijssel

Lees meer
share on Twitter Like Aanbesteding: Best Value aanbesteding Rehabilitatie Kunstwerken (P16009) - Provincie Overijssel on Facebook

Aanbesteding: Inkomensspecialist - Gemeente Haarlemmermeer

Lees meer
share on Twitter Like Aanbesteding: Inkomensspecialist - Gemeente Haarlemmermeer on Facebook

Aanbesteding: Verwerking afvalstromen - Gemeente Groningen

Lees meer
share on Twitter Like Aanbesteding: Verwerking afvalstromen - Gemeente Groningen on Facebook

Aanbesteding: 649 Baliemedewerker Bouwen - Gemeente Amstelveen

Lees meer
share on Twitter Like Aanbesteding: 649 Baliemedewerker Bouwen - Gemeente Amstelveen on Facebook

Aanbesteding: Zonnepanelen Ezingepark - Stichting Regionaal Opleidingen Centrum Drenthe

Lees meer
share on Twitter Like Aanbesteding: Zonnepanelen Ezingepark - Stichting Regionaal Opleidingen Centrum Drenthe on Facebook

Strategie implementatie – wat is jouw rol?

Lees meer
share on Twitter Like Strategie implementatie – wat is jouw rol? on Facebook

Bijeenkomst Subsidies energie-innovaties

Lees meer
share on Twitter Like Bijeenkomst Subsidies energie-innovaties on Facebook

Philips maakt haar Environmental Profit & Loss bekend, berekend door EcoChain

Lees meer
share on Twitter Like Philips maakt haar Environmental Profit & Loss bekend, berekend door EcoChain on Facebook

Maakt de GDPR marktonderzoek onmogelijk?

Lees meer
share on Twitter Like Maakt de GDPR marktonderzoek onmogelijk? on Facebook

RetailSonar opent Nederlandse vestiging

Lees meer
share on Twitter Like RetailSonar opent Nederlandse vestiging on Facebook

Open Coffee Midden-Nederland: Komende vrijdag: OCMN Conferentie

Lees meer
share on Twitter Like Open Coffee Midden-Nederland: Komende vrijdag: OCMN Conferentie on Facebook

Nederland EU-koploper vast en mobiel internet

Lees meer
share on Twitter Like Nederland EU-koploper vast en mobiel internet on Facebook

Financieel Jaarverslag 2017: voor het tweede jaar op rij een begrotingsoverschot

Lees meer
share on Twitter Like Financieel Jaarverslag 2017: voor het tweede jaar op rij een begrotingsoverschot on Facebook

Ebola bestrijden: 'Alles staat of valt met overleg met lokale bevolking'

Lees meer
share on Twitter Like Ebola bestrijden: 'Alles staat of valt met overleg met lokale bevolking' on Facebook

Sprout: HTC lanceert blockchain-smartphone; Zuckerberg 'verdient' 6,2 miljoen per dag

Lees meer
share on Twitter Like Sprout: HTC lanceert blockchain-smartphone; Zuckerberg 'verdient' 6,2 miljoen per dag on Facebook

Kabinet verbiedt elektriciteitsproductie met kolen

Lees meer
share on Twitter Like Kabinet verbiedt elektriciteitsproductie met kolen on Facebook


de ZorgSector


I Ondernemer - Utrecht, Ut 3562 CH Netherlands Email Marketing Powered by MailChimp
afmelden | bijwerken gegevens